CINECA IRIS Institutional Research Information System

COMOGLIO, Paolo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.078
EU - Europa 13.570
AS - Asia 7.653
OC - Oceania 136
SA - Sud America 131
AF - Africa 105
Continente sconosciuto - Info sul continente non disponibili 16
Totale 40.689
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.466
CN - Cina 4.965
IT - Italia 2.238
DE - Germania 1.656
IE - Irlanda 1.551
SE - Svezia 1.467
GB - Regno Unito 1.350
UA - Ucraina 1.346
FR - Francia 1.255
FI - Finlandia 895
KR - Corea 878
JP - Giappone 594
CA - Canada 566
PL - Polonia 412
ES - Italia 313
IN - India 266
VN - Vietnam 189
AT - Austria 179
NL - Olanda 165
BE - Belgio 156
SG - Singapore 147
CH - Svizzera 146
HK - Hong Kong 120
AU - Australia 110
TW - Taiwan 110
TR - Turchia 100
BR - Brasile 89
GR - Grecia 77
RU - Federazione Russa 75
RO - Romania 50
SN - Senegal 48
IR - Iran 44
DK - Danimarca 42
MX - Messico 40
PT - Portogallo 40
TH - Thailandia 40
IL - Israele 36
CZ - Repubblica Ceca 31
PK - Pakistan 29
NZ - Nuova Zelanda 26
HU - Ungheria 23
SA - Arabia Saudita 22
ID - Indonesia 19
NO - Norvegia 19
MY - Malesia 18
EG - Egitto 17
EU - Europa 12
JO - Giordania 12
UZ - Uzbekistan 12
AR - Argentina 11
CL - Cile 11
HR - Croazia 11
MU - Mauritius 10
BG - Bulgaria 9
CO - Colombia 9
RS - Serbia 9
ZA - Sudafrica 9
EE - Estonia 8
LB - Libano 8
PH - Filippine 8
SI - Slovenia 8
DZ - Algeria 7
LK - Sri Lanka 7
LT - Lituania 7
PE - Perù 7
SK - Slovacchia (Repubblica Slovacca) 7
KE - Kenya 6
LU - Lussemburgo 6
IQ - Iraq 5
AE - Emirati Arabi Uniti 4
OM - Oman 4
AM - Armenia 3
AP - ???statistics.table.value.countryCode.AP??? 3
BY - Bielorussia 3
GE - Georgia 3
IS - Islanda 3
MK - Macedonia 3
MO - Macao, regione amministrativa speciale della Cina 3
QA - Qatar 3
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
GL - Groenlandia 2
IM - Isola di Man 2
KZ - Kazakistan 2
LV - Lettonia 2
MA - Marocco 2
NG - Nigeria 2
PA - Panama 2
TN - Tunisia 2
A1 - Anonimo 1
AL - Albania 1
CR - Costa Rica 1
GH - Ghana 1
MD - Moldavia 1
ME - Montenegro 1
MM - Myanmar 1
MT - Malta 1
NP - Nepal 1
PR - Porto Rico 1
PY - Paraguay 1
Totale 40.687
Salva come PNG Salva come JPEG
Città #
Beijing 2.464
Chandler 2.410
Ann Arbor 1.897
Dublin 1.540
Houston 917
Fairfield 815
Jacksonville 806
Dearborn 641
Ashburn 607
Wilmington 598
Medford 558
Villeurbanne 510
Princeton 492
Woodbridge 471
Shanghai 436
Milan 411
Warsaw 384
Redwood City 365
Nyköping 362
Seattle 346
Torino 310
Toronto 303
Cambridge 280
Verona 226
Guangzhou 196
Boardman 193
Tokyo 182
Pisa 175
Boston 174
Vienna 160
Fremont 159
New York 149
Falls Church 144
Nanjing 142
Dong Ket 131
Lachine 111
Turin 109
Los Angeles 95
Brussels 94
Hefei 91
Zhengzhou 88
Hangzhou 86
Wuhan 79
Rome 74
Norwalk 71
Taipei 70
San Diego 68
London 67
Jinan 62
Chengdu 61
Duncan 56
Buffalo 54
Changsha 54
Shenyang 54
Singapore 52
Kunming 51
Munich 50
Madrid 48
Paris 48
Mountain View 45
Barcelona 44
Chicago 42
Ottawa 42
Seoul 41
Amsterdam 40
Helsinki 40
Nanchang 39
Washington 39
Pune 33
Xian 31
Manchester 30
Shenzhen 30
Silver Spring 30
Auburn Hills 29
Hebei 29
Dallas 28
Istanbul 28
Florence 26
San Francisco 26
São Paulo 26
Tianjin 26
Berlin 25
Fuzhou 25
Nürnberg 25
Central 24
Bangkok 22
Chongqing 22
Osaka 22
Rochester 22
Luni 21
Nashville 21
Tappahannock 21
Düsseldorf 20
Edinburgh 20
Philadelphia 20
Southend 20
Zurich 20
Aioicho 19
San Mateo 19
Vancouver 19
Totale 22.798
Salva come PNG Salva come JPEG
Nome #
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial 4.822
MET signalling: principles and functions in development, organ regeneration and cancer. 1.420
Known and novel roles of the MET oncogene in cancer: A coherent approach to targeted therapy 1.408
Induction of MET by Ionizing Radiation and Its Role in Radioresistance and Invasive Growth of Cancer 712
IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. 673
A molecularly annotated platform of patient-derived xenografts (‘xenopatients’) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer 572
MET mutations in cancers of unknown primary origin (CUPs). 426
Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer. 309
INHIBITION OF MEK AND PI3K/MTOR SUPPRESSES TUMOR GROWTH BUT DOES NOT CAUSE TUMOR REGRESSION IN PATIENT-DERIVED XENOGRAFTS OF RAS-MUTANT COLORECTAL CARCINOMAS 292
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. 262
Only a subset of Met-activated pathways are required to sustain oncogene addiction 233
Targeting the oncogenic Met receptor by antibodies and gene therapy. 221
Targeting the MET oncogene in cancer and metastases. 216
Genetic and expression analysis of MET, MACC1 and HGF in metastatic colorectal cancer: Response to Met inhibition in patient xenografts and pathological correlations 216
Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor 214
Met-driven invasive growth involves transcriptional regulation of Arhgap12 212
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients 204
A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors. 202
C-met inhibition blocks bone metastasis development induced by renal cancer stem cells 198
Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis 196
Inhibition of Src impairs the growth of met-addicted gastric tumors. 196
Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor. 194
The MET oncogene is a functional marker of a glioblastoma stem cell subtype. 193
Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. 175
Tankyrase inhibition impairs directional migration and invasion of lung cancer cells by affecting microtubule dynamics and polarity signals 175
Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies 171
Ron kinase transphosphorylation sustains MET oncogene addiction 169
Hepatocyte growth factor and its receptor, the tyrosine kinase encoded by the c-MET proto-oncogene. 166
MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. 164
Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. 162
MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. 162
A molecularly annotated model of patient-derived colon cancer stem-like cells to assess genetic and non-genetic mechanisms of resistance to anti-EGFR therapy 162
Rebound effects caused by withdrawal of MET Kinase inhibitor are quenched by a MET Therapeutic antibody 156
Agonist antibodies activating the Met receptor protect cardiomyoblasts from cobalt chloride-induced apoptosis and autophagy 151
TNF-α promotes invasive growth through the MET signaling pathway. 150
Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. 149
Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody 149
MET-Mediated Resistance to EGFR Inhibitors: An Old Liaison Rooted in Colorectal Cancer Stem Cells. 141
Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential. 140
Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family. 139
A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. 139
The tetraspanin CD151 is required for met-dependent signaling and tumor cell growth 139
Autophosphorylation promotes complex formation of recombinant hepatocyte growth factor receptor with cytoplasmic effectors containing SH2 domains. 138
The Slit/Robo system suppresses hepatocyte growth factor-dependent invasion and morphogenesis 137
Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. 136
MiR-1 Downregulation Cooperates with MACC1 in Promoting MET Overexpression in Human Colon Cancer. 136
THE EXPRESSION OF LINE1-MET CHIMERIC TRANSCRIPT IDENTIFIES A SUBGROUP OF AGGRESSIVE BREAST CANCERS 135
c-met is amplified but not mutated in a cell line with an activated met tyrosine kinase. 133
Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene. 133
Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. 130
Activation of RAS family members confers resistance to ROS1 targeting drugs. 129
MET inhibition overcomes radiation resistance of glioblastoma stem-like cells 128
A peptide representing the carboxyl-terminal tail of the met receptor inhibits kinase activity and invasive growth. 126
Protein tyrosine phosphatase PTP-S binds to the juxtamembrane region of the hepatocyte growth factor receptor Met. 125
A differentiation switch for genetically modified hepatocytes. 124
Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs. 124
Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth 123
MET/HGF co-targeting in pancreatic cancer: A tool to provide insight into the tumor/stroma crosstalk 123
A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor/scatter factor receptor 122
"Invasive-growth" signaling by the Met/HGF receptor: the hereditary renal carcinoma connection 121
Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. 121
Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. 118
Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor). 116
Biosynthesis of the protein encoded by the c-met proto-oncogene 116
Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort 115
Molecular profiling of the "plexinome" in melanoma and pancreatic cancer 114
The MET Oncogene in Glioblastoma Stem Cells: Implications as a Diagnostic Marker and a Therapeutic Target. 114
Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. 113
EXPRESSION OF MET MRNA AS PROGNOSTIC MARKER IN MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL DRUGS 112
Identification of functional domains in the hepatocyte growth factor and its receptor by molecular engineering. 110
WHEN REGULATION FAILS: HOW CANCER ARISES 108
A point mutation in the MET oncogene abrogates metastasis without affecting transformation. 108
Multinucleated giant cells in organ cultures of spleen. 107
Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors 107
Cancer of Unknown Primary (CUP): genetic evidence for a novel nosological entity? A case report 107
A 135,000 molecular weight plasma membrane glycoprotein involved in fibronectin-mediated cell adhesion. Immunofluorescence localization in normal and RSV-transformed fibroblasts. 105
MicroRNAs impair MET-mediated invasive growth 104
HGF: a multifunctional growth factor controlling cell scattering. 103
Scatter factor receptors are key players in a unique multistep program leading to invasive growth. 103
Different point mutations in the met oncogene elicit distinct biological properties. 103
[Molecular markers study in pTNM of squamous carcinoma of the head and neck] 102
A gene trap vector system for identifying transcriptionally responsive genes 102
"Active" cancer immunotherapy by anti-Met antibody gene transfer 101
Cardiac concentric hypertrophy promoted by activated Met receptor is mitigated in vivo by inhibition of Erk1,2 signalling with Pimasertib 99
HGF receptor associates with the anti-apoptotic protein BAG-1 and prevents cell death 98
HGF receptor agonists protect cardiomyocytes from CoCl2-induced cell injury 98
Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-“decoy” strategy 95
Biochemical and immunological properties of the human carcinoma-associated CAR-3 epitope defined by the monoclonal antibody AR-3. 93
Biochemical and immunological properties of the human carcinoma antigen CAR-5 defined by the monoclonal antibody BD-5. 93
[The distribution of motor plates in the mimic muscles of the dog (Canis familiaris L.)] 92
Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. 92
A positive feedback loop between hepatocyte growth factor receptor and beta-catenin sustains colorectal cancer cell invasive growth 92
An 'in-cell trial' to assess the efficacy of a monovalent anti-MET antibody as monotherapy and in association with standard cytotoxics. 91
Met Over-Expression Is a Prognostic Factor for Myeloma Patients Treated with Novel Agents 91
A comparative study of SV40-transformed fibroblast plasma membrane proteins labelled by enzymatic iodination or with trinitrobenzene sulfonate. 90
HGF/Met tyrosine kinase receptor in heart physiology and pathophysiology 89
Characterization of T lymphocytes mediating in vivo protection against RSV-induced murine sarcomas. 88
ERK: A key player in the pathophysiology of cardiac hypertrophy 88
A cell surface integral membrane glycoprotein of 85,000 mol wt (gp85) associated with triton X-100-insoluble cell skeleton. 87
The hepatocyte growth factor and its receptor. 87
Totale 22.945
Salva come PNG Salva come JPEG
Categoria #
all - tutte 100.260
article - articoli 0
book - libri 0
conference - conferenze 4.555
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 104.815
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.145 0 0 0 0 0 0 0 0 0 0 789 356
2019/20206.071 278 256 469 489 531 1.038 784 400 623 529 450 224
2020/20215.089 381 246 467 320 471 277 537 192 711 451 369 667
2021/20226.744 465 486 443 559 352 342 611 383 294 422 1.224 1.163
2022/20237.771 811 510 224 750 756 1.759 652 531 862 176 459 281
2023/20243.319 540 656 241 316 260 478 218 274 67 266 3 0
Totale 42.032